Back to top
more

Harpoon Therapy Inc. (HARP)

(Delayed Data from NSDQ)

$10.59 USD

10.59
19,408

-0.41 (-3.73%)

Updated May 3, 2019 04:13 PM ET

After-Market: $10.33 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 3.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View

Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.

Company News for Jan 9, 2024

Companies In The News Are: HELE, CMC, NVDA, MRK, HARP.

Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout

Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.

Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock?

Harpoon Therapeutics, Inc. (HARP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stock to Buy for December 5th

PDD, HARP and LEU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 5, 2023.

Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?

Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.

Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade

The consensus price target hints at a 40.5% upside potential for Harpoon Therapeutics, Inc. (HARP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Merck (MRK) to Acquire Private Neuroscience Company for $610M

Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.

New Strong Buy Stocks for November 21st

AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.

Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain

Harpoon Therapeutics, Inc. (HARP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?

The mean of analysts' price targets for Harpoon Therapeutics, Inc. (HARP) points to a 92.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

New Strong Buy Stocks for November 14th

INTC, DIBS, HARP, EME and RWAY have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2023.

Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 106.98% and 120.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 4.11% and 15.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Lags Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 26.19% and 2.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -7.28% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of -6.25% and 292.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?